LCM
JUNO

Leisure Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Leisure Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,529
Closed -$255K – 121
2017
Q2 		$255K Buy
+8,529
New +$210K 0.23% 78

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Leisure Capital Management's JUNO Position: Q3 2017 in Review

Leisure Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 8,529 shares — an estimated $255K sold.

Leisure Capital Management first reported a position in JUNO in Q2 2017 and held it in 1 quarter. The position peaked at $255K in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Leisure Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Leisure Capital Management sold 8,529 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $255K.
  • Leisure Capital Management first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Leisure Capital Management's Juno Therapeutics, Inc. position peaked at $255K in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Leisure Capital Management's 13F filing for Q3 2017, filed 24 Oct 2017.